Teacher Retirement System of Texas lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 5.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,286 shares of the medical research company's stock after selling 449 shares during the period. Teacher Retirement System of Texas' holdings in Charles River Laboratories International were worth $1,434,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. Ronald Blue Trust Inc. bought a new position in Charles River Laboratories International during the 2nd quarter valued at approximately $25,000. Pinnacle Financial Partners Inc. purchased a new stake in Charles River Laboratories International during the 3rd quarter valued at $26,000. Trust Co. of Vermont purchased a new stake in Charles River Laboratories International during the 2nd quarter valued at $29,000. Trustcore Financial Services LLC boosted its stake in Charles River Laboratories International by 72.0% during the 3rd quarter. Trustcore Financial Services LLC now owns 172 shares of the medical research company's stock valued at $34,000 after purchasing an additional 72 shares during the last quarter. Finally, SRS Capital Advisors Inc. purchased a new stake in Charles River Laboratories International during the 2nd quarter valued at $35,000. Institutional investors own 97.80% of the company's stock.
Get
Charles River Laboratories International alerts:
Insider Buying and Selling at Charles River Laboratories International
In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 2,279 shares of the firm's stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $249.90, for a total transaction of $569,522.10. Following the sale, the executive vice president now directly owns 2,499 shares of the company's stock, valued at $624,500.10. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Shannon M. Parisotto sold 2,279 shares of Charles River Laboratories International stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $249.90, for a total value of $569,522.10. Following the sale, the executive vice president now directly owns 2,499 shares of the company's stock, valued at $624,500.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Michael Gunnar Knell sold 855 shares of Charles River Laboratories International stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $248.59, for a total value of $212,544.45. Following the completion of the sale, the chief accounting officer now directly owns 6,438 shares in the company, valued at $1,600,422.42. The disclosure for this sale can be found here. Insiders have sold a total of 10,077 shares of company stock valued at $2,334,821 over the last ninety days. 1.10% of the stock is currently owned by company insiders.
Charles River Laboratories International Price Performance
Shares of Charles River Laboratories International stock opened at $245.09 on Monday. Charles River Laboratories International, Inc. has a one year low of $181.36 and a one year high of $349.84. The stock's fifty day moving average is $226.87 and its 200 day moving average is $219.23. The stock has a market cap of $12.47 billion, a P/E ratio of 28.87, a P/E/G ratio of 1.54 and a beta of 1.29. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.14 and a current ratio of 1.40.
Charles River Laboratories International (NYSE:CRL – Get Rating) last announced its earnings results on Wednesday, November 2nd. The medical research company reported $2.63 EPS for the quarter, topping analysts' consensus estimates of $2.51 by $0.12. The company had revenue of $989.16 million for the quarter, compared to analysts' expectations of $978.65 million. Charles River Laboratories International had a return on equity of 20.93% and a net margin of 11.54%. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.89 earnings per share for the current year.
Wall Street Analysts Forecast Growth
CRL has been the topic of several recent analyst reports. Jefferies Financial Group downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, January 12th. Robert W. Baird increased their target price on Charles River Laboratories International from $275.00 to $285.00 and gave the company an "outperform" rating in a research note on Wednesday, January 11th. Credit Suisse Group dropped their price target on Charles River Laboratories International from $285.00 to $280.00 and set an "outperform" rating on the stock in a research note on Thursday, November 3rd. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $280.00 to $275.00 and set an "overweight" rating on the stock in a research note on Thursday, November 3rd. Finally, William Blair restated an "outperform" rating on shares of Charles River Laboratories International in a research note on Wednesday, November 2nd. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $297.38.
Charles River Laboratories International Company Profile
(Get Rating)
Charles River Laboratories International, Inc is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.
Featured Stories
- Get a free copy of the StockNews.com research report on Charles River Laboratories International (CRL)
- Is Seagate Technology Signaling the End of its Normalization?
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
